FGF21 analogs in focus: From pathways to clinical evidence in MASH

During this interactive session, Drs Arun Sanyal and Kris Kowdley will be highlighting current gaps in the management of steatotic liver disease, reviewing the mechanisms of FGF21 analogs in MASH and discussing the clinical evidence for FGF21 analogs in MASH management. 

Industry Supporter: Novo Nordisk